Association of lung immune prognostic index with survival outcomes in patients with metastatic renal cell carcinoma...

Area of Science:

• Oncology
• Immunotherapy
• Biomarkers

Background:

• The Lung Immune Prognostic Index (LIPI) uses neutrophil-to-lymphocyte ratio and lactate dehydrogenase levels.
• LIPI is associated with survival in various cancers treated with immune checkpoint inhibitors.
• Its prognostic value in metastatic renal cell carcinoma (mRCC) receiving nivolumab plus ipilimumab is not well-established.

Purpose of the Study:

• To investigate the association between pre-treatment LIPI and survival outcomes in mRCC patients treated with nivolumab plus ipilimumab.
• To determine if LIPI can serve as a prognostic biomarker in this specific patient population.

Main Methods:

• Retrospective analysis of 156 mRCC patients treated with nivolumab plus ipilimumab across eight institutions.
• Assessment of pre-treatment LIPI scores (good, intermediate, poor).
• Evaluation of progression-free survival (PFS), second progression-free survival (PFS2), cancer-specific survival (CSS), and overall survival (OS).

Main Results:

• Patients were categorized into good (54%), intermediate (33%), and poor (13%) LIPI groups.
• While PFS did not differ significantly, LIPI groups showed significant differences in PFS2, CSS, and OS.
• High pre-treatment LIPI independently predicted poor PFS2 and OS, and poor CSS compared to good LIPI.

Conclusions:

• Pre-treatment LIPI is a significant independent predictor of poor prognosis in mRCC patients receiving nivolumab plus ipilimumab.
• LIPI can help identify patients with a worse prognosis in this treatment setting.
• These findings support the use of LIPI for risk stratification in mRCC immunotherapy.